نتایج جستجو برای: overall response rate orr

تعداد نتایج: 2165667  

Journal: :British journal of haematology 2014
Michael Wang Leslie L Popplewell Robert H Collins Jane N Winter Andre Goy Mark S Kaminski Nancy L Bartlett Patrick B Johnston John Lister Suzanne R Fanning Joseph M Tuscano J Thaddeus Beck Hakan Kaya Anna Robeva Jenna Fan Judith Klimovsky Wing Cheung Azzeddine Cherfi Owen A O'Connor

The multicentre, open-label, two-stage, single-arm, phase 2, PILLAR (PIvotaL Lymphoma triAls of RAD001)-1 study (NCT00702052) assessed the efficacy and safety of everolimus 10 mg/d in adults with confirmed mantle cell lymphoma (MCL) refractory to or intolerant of bortezomib who received ≥1 other antineoplastic agent, either separately or in combination with bortezomib. Primary endpoint was over...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
M K Kim C Suh D H Lee C-K Min S J Kim K Kim J H Moon S S Yoon G-W Lee H J Kang S-H Kim C W Choi H S Eom J-Y Kwak H J Kim Y-C Mun S-M Bang K Lee H J Shin J H Lee

BACKGROUND To analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM). DESIGN AND METHODS Seventy-five patients diagnosed with IgD MM were selected from the Korean Myeloma Registry database (www.myeloma.or.kr). RESULTS Median age was 57 years and the main presenting features were bone pain (7...

2016
Furong Kou Zhihao Lu Jian Li Xiaotian Zhang Ming Lu Jun Zhou Xicheng Wang Jifang Gong Jing Gao Jie Li Yan Li Lin Shen

To explore the influence of pretreatment lymphopenia on the toxicity and efficacy of first-line chemotherapy in patients with metastatic esophagus squamous cell carcinoma (ESCC). In total, 215 patients were included in this retrospective study. Correlations between pretreatment lymphopenia (lymphocyte count <1 × 10(9) /L) and the occurrence of toxicity and the efficacy of first-line palliative ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Xin Li Yingying Cui Zhenchang Sun Lei Zhang Ling Li Xinhua Wang Jingjing Wu Xiaorui Fu Wang Ma Xudong Zhang Yu Chang Feifei Nan Wencai Li Liping Su Jinghua Wang Hongwei Xue Mingzhi Zhang

PURPOSE Optimal treatment strategies for advanced natural killer/T (NK/T)-cell lymphoma have not been fully defined. We compared the safety and efficacy of DDGP and SMILE regimens for advanced NK/T-cell lymphoma in a randomized controlled, multicenter, and open-label clinical trial. EXPERIMENTAL DESIGN Patients were newly diagnosed in stages III-IV and had performance scores in 0 to 2. Six cy...

2005
J. C. WATERLOW John Boyd

Almost exactly IOO years ago, in fact on 23 September, 1880, John Boyd Orr was born quite near here, at Kilmaurs, Ayrshire. It is fitting that this lecture should be given in the University of Glasgow with which he had such close relations, first as a student and research assistant, and later as Rector and finally Chancellor. I think that the best way of paying tribute to this remarkable man in...

2017
Fei Li Shu-Hua Zhang Li-Min Pang

A network meta-analysis evaluating efficacy and adverse events of eight erlotinib-based therapies (erlotinib+placebo, erlotinib+tivantinib, erlotinib+celecoxib, erlotinib+onartuzumab, erlotinib+sunitinib, erlotinib+entinostat, erlotinib+sorafenib, and erlotinib+bevacizumab) for advanced/metastatic non-small-cell lung cancer (NSCLC) was performed. PubMed and Cochrane Library were reviewed, and t...

2015
Jing Yu Jing Xiao Yifan Yang Bangwei Cao Yang Liu.

The efficacy and toxicity of oxaliplatin-based versus carboplatin/cisplatin-based doublets in patients with previously untreated nonsmall cell lung cancer (NSCLC) have been compared.We searched published randomized controlled trials of oxaliplatin-based or carboplatin/cisplatin-based medications for NSCLC. A fixed effect model was used to analyze outcomes which were expressed as the hazard rati...

Journal: :Translational breast cancer research 2023

Background: Antibody-drug conjugate (ADC) is an emerging therapy that bestows advanced breast tumors with encouraging clinical activity and manageable toxicity; however, the outcomes of phase 2/3 randomized controlled trials (RCTs) are heterogeneous. Our study aims to assess utilities [i.e., objective response rate (ORR), benefit (CBR), progression-free survival (PFS), overall (OS)], treatment-...

2018
Shencun Fang Meiling Zhang Guihong Wei Kai-Hua Lu

Objectives This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. Materials and Methods We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (...

2014
Jeffrey A Meyerhardt Michele M Grady Jamie N Lowe Michele A Gargano Richard D Huhn Ada H Braun

Background Single-agent Cetuximab has been shown to improve objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in patients (pts) with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type (WT) metastatic colorectal cancer (mCRC) who failed Oxaliplatinand Irinotecan-based therapy or are intolerant to Irinotecan. The mechanism of action of Cetuxi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید